CD40LG

(redirected from CD154)
Also found in: Wikipedia.

CD40LG

A gene on chromosome Xq26 that encodes of a protein expressed on the surface of T cells which regulates B-cell function by binding CD40 to the B-cell surface. CD40LG is critical for immunoglobulin class switching. 

Molecular pathology
A defect in CD40LG is associated with hyper IgM syndrome due to an inability to undergo class switch.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
[IgG.sub.1] was as expected, according to human serum level, the most secreted IgG subclass with a concentration of 51 [+ or -] 10 [micro]g/mL following CD70 interaction and 59 [+ or -] 17 [micro]g/mL following CD154 interaction.
Boskovic et al., "CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in nonhuman primates," American Journal of Transplantation, vol.
An increased sensitivity of splenic T cells to IL-7 was observed in two models of allogenic islet transplantation in NOD recipients treated with anti-CD45RB and CD154 antibodies [33] as well as under an "Edmonton like" protocol (tacrolimus, rapamycin, and anti-CD25 antibody) [34].
While most studies involving murine lupus models have concluded the superior efficacy and safety of costimulatory blockade in treating lupus, most clinical trials which evaluated costimulatory blockers in SLE to date, such as CD154 and CTLA-4Ig, did not meet the predefined therapeutic endpoints.
Consistent with the notion that activation of B cells requires T cell helper functions (notably IL-4 secreting [T.sub.H]2 subset), the CD40 ligand (CD154) is expressed on activated T cells (reviewed in [36]).
(Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the signing of a research collaboration agreement with Massachusetts General Hospital (MGH), a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody (mAb) that targets CD154 for the prevention and treatment of organ transplant rejection.
Tonix Pharmaceuticals Holding announced the signing of a research collaboration agreement with Massachusetts General Hospital, a teaching hospital of Harvard Medical School, to develop TNX-1500, a humanized monoclonal antibody that targets CD154 for the prevention and treatment of organ transplant rejection.
Compared with the control group, the CD4+ T/CD8+ T ratio was reduced, CD154 was downregulated, CD152 was upregulated on T cell surfaces, and pro-inflammatory factors (tumor necrosis factor alpha, inducible nitric-oxide synthase, IL-1[sz]) in BV-2 cells were decreased in the experimental group.
Through this T cell-B cell interaction, B cells are stimulated by T cell-derived signals such as CD40L (CD154) essential for the survival and activation of antigen-stimulated B cells, followed by differentiation to antibody-producing cells.
Expression of costimulatory molecules such as CD40, CD154, CD80, and CD86 did not change after IFN-[gamma] treatment in any of the MSC types (data not shown).
Gill, "CD4-dependent generation of dominant transplantation tolerance induced by simultaneous perturbation of CD154 and LFA-1 pathways," Journal of Immunology, vol.
In addition, we could recently show [47] that local upregulation of proinflammatory and proosteogenic molecules such as CRP, CD40, CD154, and sAtB2 as well as galectin-3 is already present at early stages of CKD in various vessels (Figure 2), i.e., the A.